BlackBerry Short Seller Squeeze Watch
Mar 20 2013 By: George Kesarios
And CEO Thorsten Heins has some good news ahead of the report. In an interview just two days ago in the Australian Financial Review, he said:
In the context of the financial viability of the company that is where I shake my head sometimes and wonder what everyone is talking about. The company has no debt, I will report pretty good cash position by the end of March in my earnings call, so I think we did a really diligent job in, not just keeping the company afloat, but also bringing it back to health.
So we have a given that the company will report a good cash position. This is very important because it tells us that the company will not have a problem building up inventory.
I don't know what short sellers are thinking, but they better adjust their thesis as to why they have shortedthis stock to begin with, because things might get out of hand and they might be "running for cover" very soon.
By" George Kesarios
BlackBerry Short Seller Squeeze Watch
Mar 20 2013, 13:12 | about: BBRY
One by one the big firms are coming over to the BlackBerry (BBRY) camp, after having realized that the company is not going out of business after all. The latest upgrade comes from Morgan Stanley, that upgraded BlackBerry from a sell to a buy rating with a price target of $22 per share from a previous $10 per share price target.
What is interesting are the catalysts mentioned by Morgan Stanley:
The move is based on adoption of BB10 expanding gross margins and increasing average selling prices. This even assumes a lower service attachment rate and low assumptions on sales numbers.
So after Goldman Sachs, who upgraded BlackBerry with a price target of $19 per share, BlackBerry gets another very prestigious upgrade, this time from Morgan Stanley, but with a higher price target.
I am not sure what short sellers are thinking, but having two of the biggest Wall Street firms against you are not very good odds.
Another short term catalyst (AKA reason to squeeze the shorts) for the stock is the fact that on March 28, 2013 (in a very few days from now) BlackBerry will present its Q1 2013 earning results. This is important for we will finally get a sense of the company's quarterly sales and just how good the Z10 is doing on a global basis.
Because it's one thing to speculate as to how the company might be doing and how sales are progressing, and its another to actually know where we stand because we will finally have official data from the company. It will also be good to hear the company's comments and of course their forward looking guidance.
And CEO Thorsten Heins has some good news ahead of the report. In an interview just
Morning Star 5/31/13
Analysts' Ratings History for Keryx Biopharmaceuticals (NASDAQ:KERX)
Date Firm Action Company Old Rating New Rating Old Price Target New Price Target Details
5/17/2013 Oppenheimer Reiterated Rating Keryx Biopharmaceuticals (KERX) Outperform $11. Brean Murray Reiterated Rating Keryx Biopharmaceuticals (KERX) Buy $15.00 View
1/29/2013 Oppenheimer Boost Price Target Keryx Biopharmaceuticals (KERX) $11.00 View
1/29/2013 Ladenburg Thalmann Boost Price Target Keryx Biopharmaceuticals (KERX) Buy $15.00 View
1/29/2013 Stifel Nicolaus Boost Price Target Keryx Biopharmaceuticals (KERX) Buy $13.00 View
1/29/2013 MLV Capital Boost Price Target Keryx Biopharmaceuticals (KERX) Buy $15.00 View
1/28/2013 Roth Capital Boost Price Target Keryx Biopharmaceuticals (KERX) Buy $15.00
Hedge fund managers are upping their holdings of Keryx (Nasdaq : KERX ) substantially.
RA Capital Management also initiated a $32.7 million position during the quarter. The following funds were also among the new KERX investors: Peter Kolchinsky's RA Capital Management, Daniel Gold's QVT Financial, and Jeffrey Vinik's Vinik Asset Management.
Seeking Alpha By: The Value Investor 4/1/13
BlackBerry's Gross Margins And Z10 Shipments Support Bullish Case
Apr 1 2013, 10:00
Mar 6, 2013 TERMEER HENRI A Director 55,499 Direct Purchase at $6.73 per share. 373,508
Feb 18, 2013 YOUNG ROBERT CDirector 990 Direct Purchase at $6.60 per share. 6,534
Seeking Alpha Keryx: A Small Biotech With Many Catalysts
May 8 2013 By: George RHO
Considering Zerenex's efficacy, safety, and administration advantages, versus the three main rivals in the market, as well as its unique ability to provide iron benefits, Keryx's ferric citrate has the potential to becomethe leading phosphate binder in the world. We believe the shares still have considerable upside potential, to be realized in the quarters and years ahead.
" Checks indicate U.S. consumer pre-orders for the BB Z10 "have been light .
Seeking Alpha Market Currents- 3/21/13
4:11 PM Checks indicate U.S. consumer pre-orders for the BlackBerry Z10 (BBRY +1.1%) "have been light and well below expectations," says Detwiler Fenton's Jeff Johnston. AT&T began taking pre-ordersonMarch12, and Verizon 2 days later; both carriers will start actual sales within a week. He thinks FY14 BB110 sales are likely to be in the 13M-15M range, below the ~25M forecast by others
where have u been? price is going up..your just mad people discussing amrn because your a short and you lost money.
sounds like mweather is this bio guy also. FDA wants this out and at meeting fund manager said would have NDA " by June or Before" so can be anyday.
ARNA Professional Co. with Great Marketing Co. vs. VVUS With No Marketing Co.
MannKind ( MNKD )Largest option buying in equities so far
Monster Options By: Davis Russell
Acadia Has A Silver Lining In Its Playbook Seeking Alpha
Jun 5 2013,
In short, Acadia Pharmaceuticals is showing great promise in its pimavanserin trials. And, biotech fund
manager activity and FDA actions are validating my theory that pimavanserin is going to be a blockbuster drug.